Classical and Novel Biomarkers for Cardiovascular Risk Prediction in the United States

Aaron R. Folsom
Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA

Received August 30, 2012; accepted January 9, 2013; released online April 20, 2013

ABSTRACT

Cardiovascular risk prediction models based on classical risk factors identified in epidemiologic cohort studies are useful in primary prevention of cardiovascular disease in individuals. This article briefly reviews aspects of cardiovascular risk prediction in the United States and efforts to evaluate novel risk factors. Even though many novel risk markers have been found to be associated with cardiovascular disease, few appear to improve risk prediction beyond the powerful, classical risk factors. A recent US consensus panel concluded that clinical measurement of certain novel markers for risk prediction was reasonable, namely, hemoglobin A1c (in all adults), microalbuminuria (in patients with hypertension or diabetes), and C-reactive protein, lipoprotein-associated phospholipase, coronary calcium, carotid intima-media thickness, and ankle/brachial index (in patients deemed to be at intermediate cardiovascular risk, based on traditional risk factors).

Key words: risk factors; coronary disease; cardiovascular disease; epidemiology

1. CARDIOVASCULAR DISEASE RISK FACTORS AND PREVENTION

In the latter half of the twentieth century, epidemiologic studies identified many important causes of cardiovascular disease (CVD) operating at the population and individual levels. Discovery of these “classical” risk factors (high blood pressure, dyslipidemia, smoking, diabetes, physical inactivity, and Western diet), along with the development of effective population-wide and high-risk prevention approaches to risk factors, contributed to a substantial decline in CVD mortality in many developed countries. Interest in CVD prevention has expanded in the United States to the extent that the American Heart Association (AHA) now promotes not only primary prevention of CVD through control of classical risk factors but also “primordial prevention” (ie, avoidance of ever having risk factors) and “maintenance of low risk” (ie, maintaining optimal risk factor levels throughout life).

2. PREDICTION OF CARDIOVASCULAR RISK IN INDIVIDUALS

Risk prediction equations derived from epidemiologic cohort studies have proved to be useful tools in primary prevention of CVD at the individual, clinical level. The Framingham equation for estimating 10-year risk of coronary heart disease (CHD) is the most widely used risk prediction model, although others exist. The Framingham model is based on the classical risk factors, namely, age, sex, blood pressure, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, smoking, and sometimes diabetes. Clinical assessment of estimated 10-year CHD risk is promoted in order to guide hyperlipidemia treatment in the United States. Furthermore, the AHA recommends that for the purpose of CHD prevention clinicians should measure risk factors and calculate overall CHD risk in all adult patients. However, use of CHD risk prediction equations is far from universal in the United States, and physicians often simply count risk factors to characterize overall risk.

As reviewed elsewhere, some scientists have criticized the Framingham 10-year CHD risk estimation for (1) its focus on 10-year CHD risk rather than lifetime risk, (2) the strong contribution of age, which is not modifiable, to CHD prediction, (3) the uncertain generalizability of Framingham risk estimation to other populations, which seems to have been solved by population-specific recalibration, (4) a focus on CHD, rather than total CVD, which the Framingham investigators recently resolved with CVD risk equations.
85% of CHD in the United States can be prevented by attributable risk calculations suggests that, in fact, 75% to 85% of CHD risk have been widely adopted for clinical use in the United States. CHD risk have been widely adopted for clinical use in the United States.

and (5) the suboptimal accuracy of risk prediction based on the limited set of classical risk factors. However, this concern that classical risk factors are insufficiently predictive is misguided and may have been perpetuated by a long-held belief that classical risk factors explained no more than 50% of CHD occurrence. Recent evidence based on population attributable risk calculations suggests that, in fact, 75% to 85% of CHD in the United States can be prevented by avoiding classical risk factors.

### Table 1. Examples of novel biomarkers of potential interest in cardiovascular disease risk prediction

| Novel blood and urine markers | Lipid-related markers | Renal function markers | Metabolic markers | Coagulation markers | Markers of vascular function and neurohumoral activity | Inflammatory markers | Markers of oxidative stress and antioxidants | Necrosis markers | Atherosclerosis markers |
|-----------------------------|----------------------|-----------------------|------------------|-------------------|-------------------------------------------------|-------------------|---------------------------------|----------------|------------------------|
| Apolipoprotein A1           | Apolipoprotein B100   | Creatinine            | Adiponectin      | Fibrinogen         | (N-terminal pro) B-type natriuretic peptide       | C-reactive protein (CRP) | Homocysteine                   | Troponin I or T | Carotid intima-media thickness (IMT) and plaque measured by ultrasound |
| Lipoprotein-associated phospholipase A2 (LpPLA2) | Lipoprotein(a)       | Cystatin-C            | Leptin           | D-dimer           | Mid-regional pro-adrenomedullin                   | Interleukin-6 (IL-6)      | Myeloperoxidase                |                | Aortic and carotid plaque detected by MRI |
|                               |                      |                       | Insulin          |                   | Microalbuminuria                                   |                   |                                 |                | Coronary calcium (CAC) score measured by CT |
|                               |                      |                       |                   |                   |                                                  |                   |                                 |                | Ankle brachial index          |
|                               |                      |                       |                   |                   |                                                  |                   |                                 |                | Pulse wave velocity           |
|                               |                      |                       |                   |                   |                                                  |                   |                                 |                | Brachial vasoreactivity measured by ultrasound |
|                               |                      |                       |                   |                   |                                                  |                   |                                 |                | Structural                        |
|                               |                      |                       |                   |                   |                                                  |                   |                                 |                | Functional                        |
|                               |                      |                       |                   |                   |                                                  |                   |                                 |                | Vascular compliance measured by radial tonometry |
|                               |                      |                       |                   |                   |                                                  |                   |                                 |                | Microvascular reactivity measured by fingertip tonometry |
|                               |                      |                       |                   |                   |                                                  |                   |                                 |                | Genetic markers                   |
|                               |                      |                       |                   |                   |                                                  |                   |                                 |                | Candidate or discovered single-nucleotide polymorphisms (SNPs) |
|                               |                      |                       |                   |                   |                                                  |                   |                                 |                | |

**3. WHICH NOVEL RISK FACTORS MIGHT IMPROVE CARDIOVASCULAR DISEASE PREDICTION?**

Even though the classical risk factors for CVD are most important, cardiovascular epidemiologists have remained interested in identifying potential novel risk factors (Table 1). Identification of such factors could help clarify CVD pathophysiology, offer targets for intervention, or lead to improved risk stratification beyond that allowed by the Framingham equations. As Greenland pointed out, novel risk factors or biomarkers may be most useful for risk prediction and preventive decision making among patients at “intermediate” Framingham 10-year CHD risk. In contrast, novel risk factor measurement is clinically less useful in high- and low-risk patients. That is, patients at high risk of CHD (as determined using classical risk factors) require intervention regardless of the levels of novel biomarkers, and classically low-risk patients may need no intervention, even if novel biomarkers are elevated.

Methods of determining whether a new CVD biomarker adds to risk prediction in epidemiologic cohort studies have received much attention recently. It is not enough to show a novel causal or noncausal biomarker is “independently associated” with CHD. A novel biomarker must add incrementally to CVD prediction equations beyond the classical risk factors, in terms of model performance, discrimination, and calibration and event reclassification.

To assess whether a novel biomarker adds incrementally to an existing CVD risk prediction model, it should be added in a new model and compared with the existing CVD risk prediction model. The comparison should be based on the net reclassification index (NRI), which is a measure that discriminates between those who developed disease and those who did not, based on ranks. The NRI for adding a novel risk factor to a prediction model is the net increase versus decrease in the net reclassification index (NRI) should be sizable. (The C statistic is the area under the receiver operating characteristic [ROC] curve and is a measure that discriminates between those who developed disease and those who did not (Table 2). Thus, the addition of a novel risk factor to an existing CVD risk prediction model should improve the C statistic, and the net reclassification index (NRI) should be sizable. (The C statistic is the area under the receiver operating characteristic [ROC] curve and is a measure that discriminates between those who developed disease and those who did not, based on ranks. The NRI for adding a novel risk factor to a prediction model is the net increase versus decrease in risk factor categories among those who developed disease, minus that among those who did not develop disease.) A novel biomarker must have a high risk ratio to contribute incrementally to the very good CHD prediction afforded by classical risk factors. Thus, to date, few novel biomarkers of CHD risk have been widely adopted for clinical use in the United States.

Although this report is not a systematic review, Tables 3 to 6 show examples from recent cohort studies of the extent to which risk prediction models using classical risk factors, like the Framingham model, are improved by the addition of novel biomarkers. As reflected by a change in the C statistic of greater than 0.01 and an NRI of greater than 10%, structural and functional measures of subclinical atherosclerosis, like coronary artery calcium, tend to significantly improve prediction of CHD/CVD risk beyond classical risk factors (Table 3). As shown in Table 4, in most studies, inflammatory and hemostatic blood biomarkers tended to add only modestly

#### Table 2. Some measures of performance for prediction models

| Aspect                        | Measure                                     | Visualization             |
|-------------------------------|---------------------------------------------|---------------------------|
| Overall performance            | P², Brier                                   | Validation graph          |
| Discrimination                 | C statistic                                  | Receiver operating characteristic (ROC curve) |
| Calibration                    | Calibration slope                           | Calibration or validation graph |
| Reclassification               | Reclassification table                      | Cross-table or scatterplot |
|                               | Net reclassification index (NRI)             | Box plots for 2 models (1 with and 1 without a marker) |
|                               | Integrated discrimination index (IDI)       |                           |

*Derived from Reference 22.*
Table 3. Improvement in CVD/CHD prediction from addition of novel atherosclerosis markers to classical risk factor prediction models

| Study                      | Outcome | Markers Added | Δ C statistic | NRI |
|----------------------------|---------|---------------|--------------|-----|
| MESA[23]                   | CHD     | CAC           | 0.76 - 0.81  | 0.25|
| MESA[24]                   | CVD     | Small-artery elasticity | 0.77 - 0.782 | 0.11|
| Heinz Nixdorf[25]          | CHD     | CAC           | 0.68 - 0.75  | 0.22|
| Rotterdam[26]              | CHD     | CAC           | 0.72 - 0.76  | 0.14|
| ARC[27]                    | CHD     | Cardiol IM or plaque | 0.74 - 0.76 | 0.10|
| ABI Collaboration[28]      | CHD     | ABI (men)     | 0.646 - 0.655| 0.058|
|                            |         | ABI (women)   | 0.605 - 0.658| 0.058|

[4]CV, cardiovascular disease; CHD, coronary heart disease; CAC, coronary artery calcium; IMT, intima-media thickness; ABI, ankle brachial index.
[5]Change in C statistic from addition of the novel marker to a classical risk factor model.
[6]Overall net reclassification index (NRI), based on 3 categories[23,25,26] or 4 categories[24,27] of risk.

Table 4. Improvement in CVD/CHD prediction from addition of novel inflammatory or hemostatic markers to classical risk factor prediction models

| Study                      | Outcome | Markers Added | Δ C statistic | NRI |
|----------------------------|---------|---------------|--------------|-----|
| Physicians Health[28]      | CVD     | CRP, FhX      | 0.699 - 0.708| 0.05|
| ARIC[29,30]                | CHD     | CRP           | 0.767 - 0.770| 0.05|
|                            |         | D-dimer       | 0.805 - 0.803| 0.05|
|                            |         | Fibrinogen (WM) | 0.668 - 0.699| 0.05|
|                            |         | Fibrinogen (WW)| 0.793 - 0.795| 0.05|
| Framingham[31]             | CVD     | CRP           | 0.795 - 0.799| 0.06|
|                            |         | CRP           | 0.863 - 0.865| 0.12|
|                            |         | Fibrinogen (WM)| 0.758 - 0.765| 0.00|
|                            |         | Fibrinogen (WW)| 0.715 - 0.731| 0.06|
| Women’s Genome Health[32]  | CVD     | NT-pro BNP    | 0.786 - 0.796| 0.05|
|                            |         | 9p21 SNP      | 0.782 - 0.786| 0.008|
|                            |         | 9p21 SNP      | 0.796 - 0.796| 0.005|

[4]CV, cardiovascular disease; CHD, coronary heart disease; FhX, family history; IL-6, interleukin-6; CRP, C-reactive protein; WM, white men; WW, white women; BNP, B-type natriuretic peptide; FVIII, factor VIII; vWF, von Willebrand factor; hcy, homocysteine.
[5]Change in C statistic from addition of the novel marker to a classical risk factor model.
[6]Overall net reclassification index (NRI), based on 3 categories[31,33,35] or 4 categories[36,37] of risk.

Table 5. Improvement in CVD/CHD prediction from addition of novel cardiac markers to classical risk factor prediction models

| Study                      | Outcome | Markers Added | Δ C statistic | NRI |
|----------------------------|---------|---------------|--------------|-----|
| Framingham[34]             | CVD     | BNP, albumin/creat | 0.76 - 0.77 | 0.05|
| Malmo[35]                  | CHD     | MR-proADM, NT-pro BNP | 0.760 - 0.769 | 0.05|
| ARIC[36]                   | CHD     | hs-Troponin T  | 0.715 - 0.724| 0.05|
| MORGAM[37]                 | CVD     | NT-pro BNP, CRP, Troponin I | 0.67 - 0.7 | 0.11|
| Uppsala men[38]            | CVD     | Troponin I, NT-pro BNP, death | 0.69 - 0.75 | 0.26|

[CVD, cardiovascular disease; CHD, coronary heart disease; BNP, B type natriuretic peptide; albumin/creat, urine albumin/creatinine; MR-proADM, mid-regional pro-adrenomedullin; CRP, C-reactive protein.
[4]Change in C statistic from addition of the novel marker to a classical risk factor model.
[5]Overall net reclassification index (NRI), based on 3 categories[35,36] or 4 categories[37,38] of risk.

Table 6. Improvement in CVD/CHD prediction from addition of SNPs to classical risk factor prediction models

| Study                      | Outcome | Markers Added | Δ C statistic | NRI |
|----------------------------|---------|---------------|--------------|-----|
| ARIC[39]                   | CHD     | 9p21 SNP      | 0.782 - 0.786| 0.008|
| Scandinavia[40]            | CHD     | 13 SNP Score  | 0.87 - 0.87  | 0.02|
| Women’s Genome Health[41]  | CVD     | 101 SNPs      | 0.796 - 0.796| 0.005|
|                            |         | (with FhX in model) | 0.80 - 0.80 | 0.00|

[CVD, cardiovascular disease; CHD, coronary heart disease; SNP, single-nucleotide polymorphism; FhX, family history.
[5]Change in C statistic from addition of the novel marker to a classical risk factor model.
[6]Overall net reclassification index (NRI), based on 4 categories[39-41] of risk.

Table 7. ACC/AHA* guideline on CVD risk assessment in asymptomatic adults

|                   | Useful in All | Reasonable in All | Reasonable if CHD Risk is Intermediate | Not Recommended |
|-------------------|---------------|-------------------|---------------------------------------|-----------------|
| Family Hx         | ✓             |                   | ✓                                     |                 |
| HbA1c             | ✓             |                   | ✓                                     |                 |
| Microalbuminuria  | ✓             | ✓                 | ✓                                     |                 |
| CRP               | ✓             |                   | ✓                                     |                 |
| LpPLA2            | ✓             |                   | ✓                                     |                 |
| Coronary Calcium  | ✓             |                   | ✓                                     |                 |
| Carotid IMT       | ✓             |                   | ✓                                     |                 |
| Ankle/Brachial Index | ✗             |                   | ✓                                     |                 |
| Brachial Vasoreactivity | ✗           |                   | ✓                                     |                 |
| Natriuretic Peptides | ✓         |                   |                         |                 |
| Apolipoproteins   | ✓             |                   | ✓                                     |                 |
| Genetic Testing   | ✓             |                   | ✓                                     |                 |

*ACC, American College of Cardiology; AHA, American Heart Association; CVD, cardiovascular disease.
[1]In patients with hypertension or diabetes.
Source: Reference 11.

4. RECENT US CONSENSUS OPINIONS ON MEASUREMENT OF NOVEL RISK MARKERS

In 2010, a joint task force of the American College of Cardiology and AHA[11] issued guidance on which novel risk factors or biomarkers, in addition to classical risk factors, might be currently considered in CHD risk prediction (Table 7). The task force categorized family history as useful and hemoglobin A1c measurement as reasonable in all adults, and they categorized microalbuminuria assessment as reasonable in adults with hypertension or diabetes. With beyond classical risk factors (change in C statistic, <0.01; NRI, <5%). Two blood biomarkers more specifically related to cardiac dysfunction—raise-sensitivity troponin T or I and B-type natriuretic peptide (Table 5)—seem to predict CHD somewhat better than inflammatory and hemostatic markers. In contrast, although numerous CVD-related genetic loci have recently been identified,[21] genetic markers currently seem to add little to CHD risk prediction models (Table 6).
regard to more-novel biomarkers, the task force categorized measurement of C-reactive protein (CRP), lipoprotein-associated phospholipase A2 (LpPLA2), coronary calcium, carotid intima-media thickness, and ankle/brachial index to be reasonable for refining risk estimation and making clinical decisions in individuals initially classified as at intermediate CHD risk, using classical risk factors. They did not recommend assessing natriuretic peptides, apolipoproteins, or genetic markers, and they did not evaluate high-sensitivity troponin for its contribution to risk prediction. Additional evidence supporting the use of natriuretic peptides and troponin T or I in risk prediction appeared after the task force met.\textsuperscript{36,37}

5. CONCLUSION

Although enthusiasm for research on novel biomarkers of CVD risk remains high in the United States, only a few such biomarkers have been accepted as clinically useful.

ACKNOWLEDGMENTS

Conflicts of interest: None declared.

REFERENCES

1. Rose G. Sick individuals and sick populations. Int J Epidemiol. 1985;14:32–8.
2. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, et al; American Heart Association Strategic Planning Task Force and Statistics Committee. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s Strategic Impact Goal through 2020 and beyond. Circulation. 2010;121:586–613.
3. Cooney MT, Dudina A, D’Agostino R, Graham IM. Cardiovascular risk-estimation systems in primary prevention. Do they differ? Do they make a difference? Can we see the future? Circulation. 2010;122:300–10.
4. Lloyd-Jones DM. Cardiovascular risk prediction: Basic concepts, current status, and future directions. Circulation. 2010;121:1768–77.
5. Wilson PW, D’Agostino RB, Levy D, Belander AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.
6. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007;335:136.
7. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002;105:310–5.
8. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611–9.
9. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.
11. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: Executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122:2748–64.
12. D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores. Results of a multiple ethnic groups investigation. JAMA. 2001;286:180–7.
13. Pencina MJ, D’Agostino RB Sr, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation. 2009;119:3078–84.
14. Greenland P, Smith SC Jr, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people: Role of traditional risk factors and noninvasive cardiovascular tests. Circulation. 2001;104:1863–7.
15. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: The role of reclassification measures. Ann Intern Med. 2009;150:795–802.
16. Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157–72.
17. Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham Risk Score. JAMA. 2009;302:2345–52.
18. Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation. 2011;123:551–65.
19. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, et al; American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: A scientific statement from the American Heart Association. Circulation. 2009;119:2408–16.
20. Wald NJ, Morris JK. Assessing risk factors as potential screening tests. A simple assessment tool. Arch Intern Med. 2011;171:286–91.
21. O’Donnell CI, Nabel EG. Genomics of cardiovascular disease. N Engl J Med. 2011;365:2098–109.
22. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21:128–38.
23. Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD, et al. Coronary artery calcium score and risk
classification for coronary heart disease prediction. JAMA. 2010;303:1610–6.
24. Duprez DA, Jacobs DR Jr, Lutsey PL, Bluemke DA, Brumback LC, Polak JF, et al. Association of small artery elasticity with incident cardiovascular disease in older adults: the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol. 2011;174:528–36.
25. Erbel R, Möhlenkamp S, Moebus S, Schmermund A, Lehmann N, Stang A, et al; Heinz Nixdorf Recall Study Investigative Group. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis. The Heinz Nixdorf Recall Study. J Am Coll Cardiol. 2010;56:1397–406.
26. Elias-Smale SE, Proença RV, Koller MT, Kavousi M, van Rooij FJ, Hunink MG, et al. Coronary calcium score improves classification of coronary heart disease risk in the elderly. J Am Coll Cardiol. 2010;56:1407–14.
27. Nambi V, Chambless LE, Folsom AR, He M, Hu Y, Mosley T, et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: The ARIC (Atherosclerosis Risk in Communities) Study. J Am Coll Cardiol. 2010;56:1600–7.
28. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction. The Reynolds Risk Score for Men. Circulation. 2008;118:2243–51.
29. Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: The Atherosclerosis Risk in Communities Study. Arch Intern Med. 2006;166:1368–73.
30. Chambless LE, Folsom AR, Sharrett AR, Sorlie P, Couper D, Szkoł M, et al. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) Study. J Clin Epidemiol. 2003;56:880–90.
31. Wilson PW, Pencina M, Jacques P, Selhub J, D’Agostino R Sr, O’Donnell CJ. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes. 2008;1:92–7.
32. Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, Roos C, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med. 2008;358:1240–9.
33. Kim HC, Greenland P, Rossouw JE, Manson JE, Cochrane BB, Lasser NL, et al. Multimarker prediction of coronary heart disease risk: The Women’s Health Initiative. J Am Coll Cardiol. 2010;55:2080–91.
34. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631–9.
35. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engström G, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA. 2009;302:49–57.
36. Saunders JT, Nambi V, de Lemos JA, Chambless LE, Virani SS, Boerwinkle E, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011;123:1367–76.
37. Blankenberg S, Zeller T, Saarela O, Havulinna AS, Kee F, Tunstall-Pedoe H, et al; MORGAM Project. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: The MONICA, Risk, Genetics, Archiving, and Monograph (MORGAM) Biomarker Project. Circulation. 2010;121:2388–97.
38. Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107–16.
39. Brautbar A, Ballantyne CM, Lawson K, Nambi V, Chambless L, Folsom AR, et al. Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease and implications for lipid-modifying therapy in the Atherosclerosis Risk in Communities Study. Circ Cardiovasc Genet. 2009;2:279–85.
40. Ripatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, Sharma A, et al. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet. 2010;376:1393–400.
41. Paynter NP, Chasman DI, Paré G, Buring JE, Cook NR, Miletich JP, et al. Association between a literature-based genetic risk score and cardiovascular events in women. JAMA. 2010;303:631–7.
42. Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300:197–208.